Short-Term Effects of Cannabis Therapy on Spasticity in MS

INVESTIGATOR: Jody Corey-Bloom, M.D., Ph.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: Short-Term Effects of Cannabis Therapy on Spasticity in MS

PROJECT TYPE: Clinical Study

STATUS: COMPLETE

RESULTS:

Thirty-seven participants were randomized at the start of the study, 30 of whom completed the trial. Treatment with smoked cannabis resulted in a significant reduction in spasticity using an objective clinician-rated measure. The placebo-controlled trial also resulted in reduced perception of pain, although participants also reported short-term, adverse cognitive effects and increased fatigue. No serious adverse events occurred during the trial.

The full results of this study have been published in CMAJ.

ABSTRACT:

Multiple Sclerosis (MS) is the most common debilitating neurologic disease of young people, affecting at least 250,000 persons in the US, often between the ages of 20 and 40. Symptom manifestation varies considerably from person to person; however, one frequently noted concomitant is spasticity, which causes pain, spasms, loss of function and difficulties in nursing care. The present application is designed to explore the short-term effectiveness and safety of medicinal cannabis on spasticity in patients with MS. There has been significant public discussion on the potential therapeutic uses of cannabis for various neurologic conditions, including MS; however, evidence that cannabis relieves spasticity produced by MS is largely anecdotal. Large-scale trials or controlled studies to compare cannabis or THC with currently available therapies for spasticity have not been performed. There is no published evidence that cannabinoids are superior or equivalent to available anti-spasticity therapies and potential side effects of cannabis need to be clarified. This proposed two-year project aims to examine spasticity and global functioning in 30 MS patients before and after treatment with smoked cannabis in a placebo-controlled, randomized, cross-over design. It is expected that MS subjects will demonstrate improvement in spasticity but impairment on cognitive measures of attention, concentration, and memory assessed before and after medicinal cannabis treatment. Patients will be measured at baseline and for three days after each treatment initiation using sensitive measures of spasticity, cognition, neuropsychiatric features, treatment-emergent effects, and global measures of functioning. Thus, the application's primary goal is to obtain objective assays of short-term efficacy and safety in MS patients treated for spasticity with medicinal cannabis.

PUBLICATIONS:

Type:

Title:

Journal Article Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte T, Bentley H, Gouaux B. (2012). Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012 Jul 10;184(10):1143-50. doi: 10.1503/cmaj.110837. Epub 2012 May 14.
Meeting Abstract Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte T, Bentley H, Gouaux B. Short-Term Effects of Medicinal Cannabis on Spasticity in Multiple Sclerosis. Poster presented at the 60th Annual Meeting of the American Academy of Neurology (Chicago, IL). 2008.

Weed Is Everywhere, So Why Is It Still A Medical Mystery?

Seeker, June 23, 2019


Regulators hungry for evidence as FDA weighs allowing CBD in food, dietary supplements

Angelica LaVito, CNBC, May 31, 2019

Food and Drug Administration regulators grilled manufacturers and advocates Friday for evidence that CBD actually does anything they claim it does.

Companies are adding CBD, short for cannabidiol, to just about everything, including makeup, tea, pet treats and soft drinks — even though there's little data to support the many claims of its benefits. FDA regulators trying to learn more about the cannabis compound held the agency's first hearing on it Friday.

More than 100 people testified at the hearing. Speakers pushed the FDA to set up a regulatory framework to legally add CBD to food products and dietary supplements. They praised CBD and the purported benefits — and FDA panelists repeatedly asked for data. Scientists warned of the little research and many potential risks CBD brings.

Read the story here


Three years into legal cannabis and California still doesn’t have a reliable test for driving while high

Brooke Staggs, Orange County Register, May 31, 2019

Nearly three years after California voters approved a cannabis legalization bill that promised, among other things, to clarify the issue of driving while high, researchers and law enforcement have few concrete answers about a potentially deadly problem.

It’s unclear, for example, if marijuana-related arrests or car crashes have increased statewide. It’s up to each county to track that data, and many still don’t distinguish between cannabis and other drugs in their arrest and accident reports.

There also aren’t yet any reliable methods for testing whether drivers were actually impaired by marijuana when they’re behind the wheel. Research in this area is hampered by federal law and left scrambling to catch up with the wave of marijuana legalization that continues to sweep the country.

Read the rest of the article here


More News

Click here to access the CMCR news archives.

Igor Grant, MD

Marijuana as Medicine: Can We See Past the Smoke?
North American Cannabis Summit presentation January 2019 (PDF)


Igor Grant, MD

Introduction/Overview
CMCR Symposium, June 2018


Daniele Piomelli, MD, PhD, PharmD

The health impact of cannabis
CMCR Symposium, June 2018


Ziva Cooper, PhD

Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018


Iain McGregor, PhD

Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018


Copyright © 2019 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego
cmcr@ucsd.edu | HNRP |